Helen Kim - Assembly Biosciences Independent Director

ASMB Stock  USD 13.30  0.08  0.60%   

Director

Ms. Helen S. Kim is an Independent Director of Assembly Biosciences Inc. Ms. Kim joined our Board in March 2018. From November 2014 until January 2018, Ms. Kim served as executive vice president of business development at Kite Pharma, Inc. where she led all business and corporate development initiatives including its sale to Gilead in September 2017. From January 2012 to January 2014, Ms. Kim served as strategic advisor to NGM Biopharmaceuticals, Inc. and from August 2009 to January 2012, Ms. Kim served as chief business officer of NGM Biopharmaceuticals, Inc. Ms. Kims additional industry experience includes executive positions at Kosan Biosciences, Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc. and Chiron Corporationrationration. In addition to her industry experience, from August 2003 to November 2007, Ms. Kim served as chief program officer for the Gordon and Betty Moore Foundation. Currently, she serves as a director on the board of Exicure, Inc., a public company, and Peloton Therapeutics, Inc. Ms. Kim formerly served as a director and member of the audit committee of Sunesis Pharmaceuticals, Inc. and WCCT Global, Inc. and a director of Foresight Labs, VISION 4 since 2018.
Age 54
Tenure 6 years
Professional MarksMBA
Address 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone833 509 4583
Webhttps://www.assemblybio.com
Kim received a B.S. in Chemical and Biomedical Engineering from Northwestern University and an M.B.A. from the University of Chicago. Among other experiences, qualifications, attributes and skills, Ms. Kim’s extensive experience in leadership roles in biotechnology companies led to the conclusion of our Board that she should serve as a director of the Company in light of our business and structure.

Assembly Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.5471) % which means that it has lost $0.5471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0084) %, meaning that it created substantial loss on money invested by shareholders. Assembly Biosciences' management efficiency ratios could be used to measure how well Assembly Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to -1.2. In addition to that, Return On Assets is expected to decline to -0.85. At present, Assembly Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 5.3 M, whereas Non Current Assets Total are forecasted to decline to about 5.3 M.
The company currently holds 3.46 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Assembly Biosciences has a current ratio of 8.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Assembly Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Assembly Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Assembly Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Assembly to invest in growth at high rates of return. When we think about Assembly Biosciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Kimberly AlexyWestern Digital
47
Matthew MassengillWestern Digital
55
William LudenAris Water Solutions
73
David PetersAntero Midstream Partners
57
Christopher ManningAntero Midstream Partners
48
Susan BostromServiceNow
60
William MortimoreAris Water Solutions
70
Paula PriceWestern Digital
55
Richard ConnorAntero Midstream Partners
67
Kathleen CoteWestern Digital
69
P PoseidonAris Water Solutions
60
Jeffrey MillerServiceNow
68
Len LauerWestern Digital
59
Charles GiancarloServiceNow
58
Margaret GentleCheniere Energy Partners
40
Vincent PaganoCheniere Energy Partners
68
Martin ColeWestern Digital
61
Jonathan ChadwickServiceNow
54
Peter KaganAntero Midstream Partners
49
Paul KorusAntero Midstream Partners
60
RiekertAris Water Solutions
N/A
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Assembly Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 70 people. Assembly Biosciences (ASMB) is traded on NASDAQ Exchange in USA. It is located in 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 68 people. Assembly Biosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Assembly Biosciences Leadership Team

Elected by the shareholders, the Assembly Biosciences' board of directors comprises two types of representatives: Assembly Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Assembly. The board's role is to monitor Assembly Biosciences' management team and ensure that shareholders' interests are well served. Assembly Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Assembly Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Nicole White, Chief Officer
John McHutchison, President CEO, Director
Adam Zlotnick, Chief CoFounder
Uri Lopatin, Vice President - Research & Development, Chief Medical Officer
Helen Kim, Independent Director
Myron Holubiak, Independent Director
Anthony Altig, Independent Director
Richard Colonno, Chief Scientific Officer
Thomas Rollins, Chief Development Officer
Shannon Ryan, Corporate Relations
Anuj MD, Chief Officer
David Houck, Senior Vice President - Product Development and Portfolio Management
AO FRACP, CEO Director
Jason Okazaki, President CEO
Uri MD, CoFounder Advisor
Michele Anderson, Chief Officer
Dr IV, Chief Officer
Lee Arnold, Chief Scientific Officer
Jacqueline Papkoff, Senior Vice President Chief Scientific Officer Microbiome
Graham Cooper, CFO, COO and Principal Financial Officer and Principal Accounting Officer
Jeanette Bjorkquist, Executive Treasury
William Ringo, Non-Executive Chairman of the Board
Susan Mahony, Director
Richard DiMarchi, Director
Miguel Barbosa, Chief Scientific Officer, Head of Microbiome Program
Steven Knox, Senior Vice President - Clinical Development
Tharaknath Rao, Head VP
Mark Auerbach, Independent Director
MHROD SHRMSCP, Chief Officer
Derek Small, Co-Founder, CEO and President and Director
Alan Lewis, Director
David Barrett, CFO, COO

Assembly Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Assembly Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Assembly Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Assembly Biosciences' short interest history, or implied volatility extrapolated from Assembly Biosciences options trading.

Pair Trading with Assembly Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Assembly Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Assembly Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Assembly Stock

  0.75EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Assembly Stock

  0.86MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.86VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.82KA Kineta Inc Report 29th of March 2024 PairCorr
  0.72CALT Calliditas Therapeutics Financial Report 21st of May 2024 PairCorr
  0.7MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to Assembly Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Assembly Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Assembly Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Assembly Biosciences to buy it.
The correlation of Assembly Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Assembly Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Assembly Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Assembly Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Assembly Stock analysis

When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Transaction History
View history of all your transactions and understand their impact on performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Is Assembly Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(17.16)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.55)
Return On Equity
(1.01)
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.